About the Company
We do not have any company description for Immunocore Holdings plc at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Immunocore Holdings plc
Immunocore Holdings plc to Announce Fourth Quarter and Full ... - Nasdaq
Immunocore Holdings plc to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 February 19, 2025 — 07:12 am EST Written by None for Quiver Quantitative -> ...
Immunocore’s Earnings Call Highlights Robust Growth and Strategic Expansion
Immunocore Holdings Plc (($IMCR)) has held its Q2 earnings call. Read on for the main highlights of the call. Immunocore Holdings Plc’s recent ...
Immunocore Holdings plc (NASDAQ:IMCR) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 9, 2025 Operator: Greetings, and welcome to the Immunocore conference call and webcast. [Operator Instructions] As a reminder, this conference is being recorded ...
IMCR | Immunocore Holdings PLC ADR Profile | MarketWatch
Immunocore Holdings PLC ADR 92 Park Drive Milton Park Abingdon, Oxfordshire OX14 4RY Phone44 123-5438600 IndustryBiotechnology SectorHealth Care/Life Sciences Fiscal Year-end12/2025 Revenue$310.33M ...
Immunocore Holdings plc (IMCR): This Small-Cap Stock Is Ready To ...
Immunocore Holdings plc (NASDAQ:IMCR) has a robust pipeline of products currently in the clinical stage including brenetafusp, which is a treatment for melanoma, a type of skin cancer.
Immunocore Holdings plc (IMCR): Among Stocks Receiving the Most Insider ...
Immunocore Holdings plc (NASDAQ: IMCR) Total Value of Insider Purchases In March: $23.99 million Market Capitalization: $1.44 billion ...
Immunocore Holdings PLC (IMCR) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Immunocore Holdings PLC (IMCR) reports robust KimTrac sales and global expansion, while navigating challenges in clinical trials and regulatory landscapes.
Immunocore Holdings plc (IMCR) Q4 2024 Earnings Call Transcript
Immunocore Holdings plc (NASDAQ: IMCR) Q4 2024 Earnings Conference Call February 26, 2024 8:00 AM ET Company Participants Clayton Robertson - Head, IR Bahija Jallal - CEO Travis Coy - CFO and Head ...
Immunocore Holdings plc: Immunocore reports second quarter financial results and provides a business update
KIMMTRAK® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 Dose selection for PRISM-MEL-301 ...
Immunocore Holdings plc (NASDAQ:IMCR) Shares Sold by Squarepoint Ops ...
Immunocore Holdings plc has a 1 year low of $23.15 and a 1 year high of $49.05. Immunocore (NASDAQ:IMCR – Get Free Report) last issued its earnings results on Wednesday, May 7th.
Immunocore Holdings PLC Sponsored ADR (IMCR) Upgraded to Buy ... - Nasdaq
Immunocore Holdings PLC Sponsored ADR (IMCR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend ...
Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript
Immunocore Holdings plc (NASDAQ: IMCR) Q4 2023 Earnings Conference Call February 28, 2024 8:00 AM ET Company Participants Clayton Robertson - Head, IR Bahija Jallal - CEO Ralph Torbay - Head ...
Similar Companies
Loading the latest forecasts...